Stelac Advisory Services LLC acquired a new position in Zoetis Inc. (NYSE:ZTS – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 18,064 shares of the company’s stock, valued at approximately $1,275,000.
Several other institutional investors and hedge funds have also bought and sold shares of ZTS. Clark Estates Inc. NY bought a new position in Zoetis in the third quarter worth $2,489,000. South Dakota Investment Council lifted its position in Zoetis by 5.8% during the third quarter. South Dakota Investment Council now owns 624,249 shares of the company’s stock valued at $43,591,000 after buying an additional 34,147 shares during the period. Rothschild Investment LLC purchased a new position in Zoetis during the third quarter valued at $112,000. Sompo Asset Management Co. Ltd. boosted its holdings in shares of Zoetis by 33.9% during the 3rd quarter. Sompo Asset Management Co. Ltd. now owns 5,731 shares of the company’s stock valued at $400,000 after buying an additional 1,451 shares in the last quarter. Finally, First Eagle Investment Management LLC bought a new stake in shares of Zoetis during the 3rd quarter valued at $50,679,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.
Zoetis Stock Down 1.3%
ZTS opened at $83.32 on Wednesday. The stock has a market capitalization of $33.85 billion, a price-to-earnings ratio of 14.17, a PEG ratio of 1.22 and a beta of 0.67. The firm has a 50 day moving average price of $76.64 and a 200-day moving average price of $91.18. Zoetis Inc. has a twelve month low of $68.77 and a twelve month high of $132.49. The company has a quick ratio of 1.40, a current ratio of 2.35 and a debt-to-equity ratio of 2.51.
Zoetis (NYSE:ZTS – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.51 by $0.24. Zoetis had a net margin of 26.15% and a return on equity of 85.90%. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter last year, the company posted $1.70 earnings per share. The firm’s quarterly revenue was down 1.3% on a year-over-year basis. Equities research analysts forecast that Zoetis Inc. will post 6.29 earnings per share for the current year.
Zoetis Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Friday, October 30th. Zoetis’s dividend payout ratio (DPR) is 36.05%.
Analysts Set New Price Targets
Several research analysts recently issued reports on ZTS shares. William Blair lowered shares of Zoetis from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 6th. UBS Group boosted their price objective on shares of Zoetis from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 27th. Jefferies Financial Group boosted their price objective on shares of Zoetis from $83.00 to $85.00 in a research note on Friday, November 6th. Citigroup cut their price objective on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Finally, BNP Paribas Exane decreased their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a research note on Tuesday, August 11th. Eight research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $101.25.
Get Our Latest Stock Analysis on ZTS
Zoetis Profile
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
Featured Stories
- Five stocks we like better than Zoetis
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
